Crinetics outlines 2024 milestones: paltusotine Phase 3 data Q1, CRN04894 data Q2

Crinetics Pharmaceuticals, Inc.

Phase 3 PATHFNDR-2 trial of paltusotine in acromegaly on track for topline data in Q1 2024.
Phase 2 trial of paltusotine in carcinoid syndrome topline data expected H1 2024; Phase 3 start H2 2024.
Phase 2 trials of CRN04894 (ACTH antagonist) in CAH and Cushing's disease initial data expected Q2 2024.
Preclinical evaluation ongoing for oral small molecules in hyperparathyroidism, PKD, Graves', TED, diabetes, and obesity.
CEO to present at J.P. Morgan Healthcare Conference on Jan 9, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.